Mycolic Acid Biosynthesis Inhibitors: Definition and Importance
Mycolic acid biosynthesis inhibitors are a critical class of antimicrobial agents, primarily utilized in the treatment of tuberculosis (TB), which is caused by the bacterium *Mycobacterium tuberculosis* (Mtb). The defining feature of Mycobacteria is a unique, complex, and highly impermeable cell envelope, of which mycolic acids are the most abundant and essential lipid component. These very long-chain (C60–C90), alpha-alkyl, beta-hydroxy fatty acids are covalently attached to the cell wall’s arabinogalactan layer and are also present as ‘free’ lipids like trehalose dimycolate (TDM), also known as cord factor. The presence of this waxy, lipid-rich layer provides the bacteria with natural resistance to desiccation, chemical damage, many conventional antibiotics, and importantly, enables the pathogen to survive and proliferate within host macrophages. By inhibiting the synthesis, modification, or transfer of mycolic acids, this class of drugs fundamentally compromises the structural integrity and protective barrier of the mycobacterial cell wall, making the bacterium susceptible to the host immune system and other co-administered antibiotics. The selective toxicity of these inhibitors stems from the fact that the mycolic acid synthesis pathway is unique to the mycobacterial taxon and is absent in human cells, making it an excellent drug target.
The Mycolic Acid Biosynthesis Pathway
The biosynthesis of mycolic acids is a complex, multi-stage process involving two distinct yet linked fatty acid synthase (FAS) systems. The overall pathway is divided into two main components: the synthesis of the “short” alpha-alkyl branch and the synthesis of the “long” meromycolic acid chain. The process begins with the multifunctional, eukaryotic-like Fatty Acid Synthase I (FAS-I), which generates C16–C18 and C24–C26 saturated fatty acids. The C24–C26 fatty acids serve as the precursor for the alpha-alkyl branch. Subsequently, the C16 or C18 products from FAS-I are channeled into the highly specialized, acyl carrier protein (ACP)-dependent Fatty Acid Synthase II (FAS-II) system. FAS-II is responsible for the processive elongation of the fatty acid chain, ultimately forming the very long meromycolic acid chain (C48–C64). This meromycolic chain then undergoes various modifications, including the introduction of cyclopropane rings, ketones, or methoxy groups, which are crucial for virulence and cell wall fluidity. Finally, a Claisen-type condensation reaction, catalyzed by the polyketide synthase Pks13 and FadD32, links the alpha-branch and the meromycolic acid chain, followed by a final reduction step to yield the mature mycolic acid. The final step involves mycolyltransferases, which transfer the mycolic acids onto the cell wall skeleton (arabinogalactan) or various trehalose-based lipids.
Key Examples and Mechanisms of Inhibition
Several drugs target different steps of this intricate pathway. The most notable inhibitors include Isoniazid, Ethionamide, and Delamanid.
Isoniazid (INH) is a cornerstone first-line antituberculosis drug. It is a prodrug that requires activation by the mycobacterial catalase-peroxidase enzyme, KatG. Once activated, the isonicotinyl radical reacts with NAD(H) to form an isonicotinyl-NAD adduct. This complex acts as a potent competitive inhibitor of InhA, the NADH-dependent enoyl-ACP reductase enzyme of the FAS-II elongation cycle. Inhibition of InhA blocks the essential reductive step, preventing the synthesis and elongation of the meromycolic acid chain, which is crucial for the cell wall’s structure.
Ethionamide (ETH) is a second-line structural analog of INH. Like INH, it is a prodrug, but it is activated by a different enzyme, the FAD-containing monooxygenase EthA. The activated ETH similarly targets the InhA enzyme, leading to the same catastrophic inhibition of FAS-II-mediated meromycolic acid synthesis. ETH is often used in cases where resistance to INH has developed via KatG mutations, although it remains susceptible to InhA-specific resistance mechanisms.
Isoxyl (Thiocarlide) and Thioacetazone (TAC) are older antitubercular drugs that have been shown to inhibit mycolic acid synthesis. Both are thought to act on the dehydratase step of the FAS-II cycle, specifically targeting HadA and HadC enzymes. This inhibition results in the accumulation of 3-hydroxy fatty acids, indicating a blockage in the removal of water needed for chain elongation.
Delamanid (OPC-67683) is a newer agent, a nitro-dihydro-imidazooxazole derivative, approved for multi-drug-resistant TB (MDR-TB). It acts by specifically inhibiting the final steps of mycolic acid synthesis, likely by interfering with the condensation reaction involving Pks13 and FadD32, or subsequent steps, thereby preventing the formation of mature mycolic acids.
Thiolactomycin (TLM) is an antibiotic obtained from *Nocardia* species. It specifically targets the β-ketoacyl-ACP synthases mtFabH and mtFabB, which are involved in initiating and continuing the elongation cycles within the FAS-II system, contributing to the inhibition of mycolic acid biosynthesis.
In addition to biosynthesis, the mycolic acid transport system is also a target. Drugs like Au1235 (MmpL3 inhibitors) target the MmpL3 transporter, which is essential for translocating trehalose monomycolate across the inner membrane for final cell wall assembly. Abolishing this transport step is a unique and effective mode of action.
Mechanisms of Resistance
The widespread issue of drug resistance significantly compromises the efficacy of mycolic acid biosynthesis inhibitors, particularly in the context of MDR and extensively drug-resistant (XDR) TB. The resistance mechanisms are well-elucidated and are often target-specific:
Resistance to Isoniazid (INH) is most commonly mediated by mutations in the *katG* gene, which codes for the catalase-peroxidase enzyme required for INH activation. Loss-of-function mutations in *katG* prevent the conversion of INH into its active form, rendering the drug ineffective. Secondary resistance mechanisms involve mutations or overexpression of the *inhA* gene, which can decrease the binding affinity of the active INH-NAD adduct, or increase the amount of target enzyme, respectively, effectively bypassing inhibition.
Resistance to Ethionamide (ETH) often involves mutations in the *ethA* gene, which codes for the monooxygenase required for its activation. Similar to INH resistance, this prevents the prodrug from becoming active. ETH resistance can also arise from mutations or overexpression of *inhA*, as both INH and ETH target the same enzyme.
Resistance to Isoxyl and Thioacetazone has been linked to missense mutations in the *hadA* and *hadC* genes, which code for the dehydratase enzymes in the FAS-II pathway. These mutations are sufficient to confer high-level resistance to both drugs, suggesting a shared mechanism of action and resistance.
For newer drugs like Delamanid, resistance can emerge through mutations in the *fadD32* gene, which encodes the acyl-AMP ligase necessary for the condensation step, or through mutations in the genes responsible for the drug’s activation or efflux, although the full spectrum of resistance mechanisms continues to be an area of active research.
Conclusion: Significance in Anti-TB Chemotherapy
Mycolic acid biosynthesis inhibitors are not merely drugs; they are an indispensable strategic component of antituberculosis chemotherapy. Their function, rooted in targeting a metabolic pathway unique to the pathogen, provides the foundation for current first-line and second-line treatments. The critical challenge lies in the rapid evolution of resistance, which necessitates a continued effort to discover new compounds that inhibit novel targets within the mycolic acid pathway, such as mtFabH or FadD32, or that target the translocation process via MmpL3. A multi-drug regimen, including mycolic acid inhibitors, remains the cornerstone of effective TB control, underscoring the enduring significance of this class of compounds in global health.